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Hyperuricemia has been shown to be associated with ventricular arrhythmias. However, the mechanisms
remained unknown. We assessed whether different urate-lowering agents can attenuate arrhythmias
through lowering urate itself or inhibiting xanthenes oxidize (XO) activity in infarcted rats. Male Wistar
rats after ligating coronary artery were randomized to either allopurinol, or febuxostat, chemically un-
related inhibitors of XO, benzbromarone or vehicle for 4 weeks. Post-infarction was associated with
increased oxidant stress, as measured by myocardial superoxide, isoprostane, XO activity and dihy-
droethidine ﬂuorescence staining. Measurement of myocardial norepinephrine levels revealed a signif-
icant elevation in vehicle-treated infarcted rats compared with sham-operated rats. Sympathetic
hyperinnervation was blunted after administering both XO inhibitors, assessed by immunoﬂuorescent
analysis, Western blotting and real-time quantitative RT-PCR. Besides, the XO inhibitors-attenuated nerve
growth factor levels were reversed in the presence of peroxynitrite generator. Arrhythmic scores in the
XO inhibitors-treated infarcted rats were signiﬁcantly lower than that in vehicle. For similar levels of
urate lowering, the uricosuric agent benzbromarone had no beneﬁcial effects on oxidative stress, sym-
pathetic hyperinnervation or arrhythmia vulnerability. Chronic use of XO inhibitors, but not uricosuric
agent, down-regulated sympathetic innervation probably through a superoxide-dependent pathway and
plays a role in the beneﬁcial effect on arrhythmogenic response.
© 2016 The Authors. Production and hosting by Elsevier B.V. on behalf of Japanese Pharmacological
Society. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/
licenses/by-nc-nd/4.0/).1. Introduction
Hyperuricemia is independently associated with a worse prog-
nosis in a wide cohort of patients with cardiovascular disease (1).
Patients with angiographically conﬁrmed coronary artery disease
with serum urate levels in the upper quartile were ﬁve times more
likely to die than those in the lowest quartile (2). Furthermore,
allopurinol treatment may provide a survival beneﬁt among pa-
tients with hyperuricemia (3). However, the debate is ongoingartment of Internal Medicine,
ical University, Taiwan, ROC.
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d/4.0/).whether urate itself is actively involved in these processes or
whether it functions merely as an indicator of xanthine oxidase
(XO) activity (4). Serum urate may increase because of increased
generation, decreased excretion, or a combination of the two.
Therefore, this study was designed to test different effects of
lowering urate agents by either XO inhibition or uricosuric treat-
ment without XO inhibition on arrhythmia after myocardial
infarction (MI), a condition of high oxidative stress and high
arrhythmia-induced mortality (5,6).
XO uses xanthine and hypoxanthine as reducing substrates and
yields both superoxide and H2O2 via 1- and 2-electron reductions of
molecular oxygen (7). XO has been implicated in a variety of
pathophysiological states in the cardiovascular system, such as left
ventricular (LV) dysfunction after MI (5). XO expression and activ-
ity, as determined by electron spin resonance spectroscopy, were
found to be markedly increased in the remote myocardium of micenese Pharmacological Society. This is an open access article under the CC BY-NC-ND
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increased oxidative stress in adverse LV remodeling after MI (8).
Blocking XO-generated oxygen radical accumulation has emerged
as an intriguing new treatment option for preventing oxygen
radical accumulation and its adverse effects on ventricular
remodeling (5). However, it remained unknown whether this
therapeutic approach translates into meaningful beneﬁcial patho-
physiological changes in terms of postinfarction arrhythmias.
Increased sympathetic nerve density afterMI has been shown to
be responsible for the occurrence of lethal arrhythmias and sudden
cardiac death in humans (9). Four weeks after MI, regional increase
of sympathetic nerves was commonly observed at the remote zone
(10). Nerve growth factor (NGF) is a prototypic member of the
neurotrophin family, members of which are critical for the differ-
entiation, survival, and synaptic activity of the peripheral sympa-
thetic and sensory nervous systems (11). The NGF promoter
contains activator protein-1 (12), which is subjected to redox
regulation through its conserved cysteine residue (13). Previous
studies have shown that peroxynitrite, the byproduct of NO and
superoxide (O2), is an important trigger of NGF formation (14). A
brief exposure to peroxynitrite induces NGF expression and secre-
tion in astrocytes (14).
Hyperuricemia has been shown to be associated with ventric-
ular arrhythmias (15). Up-regulated XO enzymatic activity is
recognized as the key pathophysiologic feature of hyperuricemia
(16). The pharmacodynamics of allopurinol are complex because
XO forms 2 very different molecules, urate and free radicals.
Recently, we have shown that free radicals can modulate the pro-
duction of neurotrophic factor (17). Thus, the purpose of this study
was 1) to investigate whether chronic administration of urate-
lowering agents results in attenuated hyperinnervation of the
heart and decreased arrhythmias through attenuated expression of
NGF, and 2) to further conﬁrm the role of free radicals in sympa-
thetic innervation in a rat MI model by using a nonpurine selective
XO inhibitor, febuxostat.
2. Materials and methods
2.1. Animals
The animal experiment was approved and conducted in accor-
dance with local institutional guidelines for the care and use of
laboratory animals and conformed with the Guide for the Care and
Use of Laboratory Animals published by the US National Institutes of
Health (NIH Publication No. 85-23, revised 1996).
2.1.1. Experiment 1 (in vivo)
Male normouricemic Wistar rats aged 8 weeks (200e250 g)
were subjected to ligation of the anterior descending artery as
previously described (18) resulting in infarction of the LV free wall.
Rats were randomly assigned into either vehicle (saline), benz-
bromarone (10 mg/kg per day), allopurinol (50 mg/kg per day,
Sigma, St. Louis, MO), or febuxostat (5mg/kg per day, Teijin Limited,
Yamaguchi, Japan). To conﬁrm the role of sympathetic hyperin-
nervation in arrhythmic vulnerability, we added an infarcted group
treated with carvedilol (b-adrenoceptor blocking agent: 5 mg/kg
per day, Sigma; n ¼ 7) (19). The doses of benzbromarone, allopu-
rinol and febuxostat used in this study have been shown to effec-
tively decrease urate levels without signiﬁcantly changing blood
pressure (20e22).
The drugs were started 24 h after infarction, at a timewhen they
could produce maximum beneﬁts (23). The study duration was
designed to be 4 weeks because the majority of the myocardial
remodeling process in the rat (70e80%) is complete within 3 weeks
(24). The drugs were administered by daily oral gavage. Shamoperated rats served as controls to exclude the possibility that the
drugs themselves directly altered sympathetic innervation. In each-
treated group, drugs were withdrawn about 24 h before the end of
the experiments in order to eliminate their pharmacological actions.
2.1.2. Experiment 2 (ex vivo)
To further conﬁrm the mechanism by which XO inhibitors act as
antioxidants, a peroxynitrite generator (3-morpholinosydnonimine,
SIN-1) was used in an ex vivo model. Four weeks after induction of
MI by coronary ligation, infarcted rat hearts were isolated and
subjected to no treatment (vehicle), allopurinol (10 mM), febuxostat
(15 mM), allopurinol þ SIN-1 (37 mM) and febuxostat þ SIN-1. The
doses of allopurinol, febuxostat and SIN-1 have been shown to be
effective in modulating biological activities (25e27). In order to
preclude non-speciﬁc actions to SIN-1, the relatively low concen-
tration of SIN-1 was used. The heart was perfused as previously
described (25). The drugs were infused for 30 min. At the end of the
study, all hearts (n ¼ 5 each group) were used for myocardial per-
oxynitrite measurement and Western analysis for NGF protein at
the remote zone (>2 mm outside the infarct).
2.2. Hemodynamics and infarct size measurements
Hemodynamic parameters and infarct size were measured in
anesthetized rats at the end of the study as described in detail in the
Supplementary material online.
2.3. In vivo electrophysiological studies
Following arterial pressure measurement, the rats were intu-
bated. Electrophysiological studies were performed as previously
described (25). Occurrence of ventricular arrhythmias was analyzed
according to an 8-point arrhythmia score. For a detailed method,
please refer to the Supplementary material online.
2.4. Real-time reverse transcription-polymerase chain reaction (RT-
PCR) of NGF
Real-time quantitative RT-PCR was performed from samples
obtained from the remote zone with the TaqMan system (Prism
7700 Sequence Detection System, PE Biosystems) as previously
described (25). For a detailed method, please refer to the
Supplementary material online.
2.5. Western blot analysis of NGF
Samples were obtained from the remote zone at week 4 after
infarction. Rabbit polyclonal antibodies to NGF (Chemicon, CA,
USA) were used. Western blotting procedures were described
previously (25). Experiments were replicated three times and re-
sults expressed as the mean value.
2.6. Immunoﬂuorescent studies of tyrosine hydroxylase, growth
associated factor 43, and neuroﬁlament
In order to investigate the spatial distribution and quantiﬁcation
of sympathetic nerve ﬁbers, analysis of immunoﬂuorescent stain-
ing was performed on LV muscle from the remote zone. Tissues for
assessing sympathetic innervation were incubated with anti-
tyrosine hydroxylase (1:200; Chemicon, CA, USA), anti-growth
associated protein 43 (a marker of nerve sprouting, 1:400; Chem-
icon, CA, USA), and anti-neuroﬁlament antibodies (a marker of
sympathetic nerves, 1:1000; Chemicon, CA, USA) in 0.5% BSA in PBS
overnight at 37 C. The analysis of the immunoﬂuorescent staining
is described in detail in the Supplementary material online.
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For evaluating myocardial intracellular superoxide production
using in situ dihydroethidium (DHE, Invitrogen Molecular Probes,
Eugene, OR, USA) ﬂuorescence, Optimal Cutting Temperature-
embedded tissues were sectioned (10 mm) at 20 C as previ-
ously described (25).
2.8. Laboratory measurements
Blood samples from the aorta were assayed at the end of the
study. Blood samples were immediately centrifuged at 3,000g for
10 min, and the serum was stored at 70 C until further analysis.
The serum urate concentration was measured by the colorimetric
uricase method using a commercial kit (King Diagnostics).
Although heart innervationwas detected by immunoﬂuorescent
staining, it did not imply that the nerves are functional. Thus, to
examine the sympathetic nerve function, we measured LV
norepinephrine levels from the remote zone. Total norepinephrine
was measured using a commercial ELISA kit (Noradrenalin ELISA,
IBL Immuno-Biological Laboratories Co., Hamburg, Germany).
Superoxide production by myocardium from the remote zone
was measured using lucigenin (5 mM bis-N-methylacridinium ni-
trate, Sigma, St. Louis, MO) enhanced chemiluminescence as pre-
viously described (28). The speciﬁc chemiluminescence signal was
calculated after subtraction of background activity and expressed as
counts per minute per milligram weight (cpm/mg).
To estimate myocardial peroxynitrite formation, we measured
free nitrotyrosine (as a marker for peroxynitrite formation) by
ELISA (Cayman Chemical, Ann Arbor, MI, USA) in myocardial ho-
mogenates as described (29).
Myocardial tissue free 15-F2t-isoprostane, a reliable index for
in vivo oxidative stress-induced lipid peroxidation (29), was
measured by using an EIA kit (Cayman chemical, Ann Arbor, USA).
The values of cardiac tissue 15-F2t-isoprostane were expressed as
pg/g tissue.
XO activity of remote myocardium was determined by the
method of Westerfeld et al (30). A diluted sample was added to
xanthine (0.1 mM) (dissolved in sodium phosphate buffer, 50 mM;
pH 7.5). XO activity was measured at 25 C on a spectrophotometer
at 290 nm for 3 min. One unit of XO activity was deﬁned as 1 mmol
urate formation/min at 25 C. XO activity was expressed as U/g
protein for speciﬁc activity.
2.9. Statistical analysis
Results were presented as mean ± SD. Statistical analysis was
performed using the SPSS statistical package (SPSS, version 18.0,
Chicago, Illinois). Differences among the groups of rats were tested
by an ANOVA. In case of a signiﬁcant effect, the measurements
between the groups were compared with Bonferroni's correction.
Electrophysiological data (scoring of programmed electrical
stimulation-induced arrhythmias) were compared by a Krus-
kaleWallis test followed by a ManneWhitney test. Probability
values were 2-tailed, and a value of P < 0.05 was considered
signiﬁcant.
3. Results
3.1. Part 1. In vivo study
Differences in mortality among the infarcted groups were not
found throughout the study. Either benzbromarone, allopurinol
or febuxostat had little effect on cardiac gross morphology in the
sham-operated rats (data not shown). Four weeks after infarction,the infarcted area of the LV was very thin and was totally replaced
by fully differentiated scar tissue. The weight of the LV inclusive
of the septum remained essentially constant for 4 weeks among
the infarcted groups (Table 1). The vehicle- or benzbromarone-
treated infarcted groups had an increase in lung weight/body
weight ratio, compared with allopurinol- or febuxostat-treated
infarcted groups. LV end-systolic pressure, LV end-diastolic
pressure, and infarct size did not differ among the infarcted
groups. Signiﬁcant reductions in þdP/dt and dP/dt were evident
in infarcted groups treated with vehicle or benzbromarone,
compared with infarcted groups treated with allopurinol or
febuxostat.3.1.1. Serum urate and norepinephrine levels
MI signiﬁcantly increased serum urate levels relative to sham
(Table 1). As expected, benzbromarone, allopurinol and febuxostat
signiﬁcantly decreased serum urate in the infarcted groups to a
similar extent. These data suggested that allopurinol and febuxo-
stat were given at similar XO inhibitory doses.
To investigate the possible role of cardiac norepinephrine syn-
thesis, we determined the LV norepinephrine levels. Either benz-
bromarone, allopurinol or febuxostat administration did not affect
tissue norepinephrine concentrations in sham-operated rats (data
not shown). LV norepinephrine levels were signiﬁcantly upregu-
lated 2.2-fold in the vehicle-treated infarcted rats in comparison
with sham (2.75 ± 0.32 vs. 1.25 ± 0.17 mg/g protein, P < 0.001).
When compared with vehicle- and benzbromarone-treated
infarcted rats, allopurinol- and febuxostat-treated infarcted rats
had signiﬁcantly lower LV norepinephrine (Table 1).3.1.2. Myocardial superoxide, free 15-F2t-isoprostane and XO
activities
Superoxide production was signiﬁcantly increased in remote LV
tissues from vehicle-treated infarcted rats compared with sham
(Fig. 1A). They were signiﬁcantly decreased in allopurinol- and
febuxostat-treated rats to the level of sham. However, when
compared with allopurinol-treated infarcted rats, benzbromarone-
treated infarcted rats had signiﬁcantly higher myocardial super-
oxide levels.
Myocardial free 15-F2t-isoprostane in vehicle-treated infarcted
rats signiﬁcantly increased as compared to sham (P < 0.01, Fig. 1B).
Myocardial free 15-F2t-isoprostane in febuxostat-treated infarcted
rats can be reduced to the levels similar to those in the allopurinol-
treated infarcted rats. However, when compared with allopurinol-
and febuxostat-treated infarcted rats, benzbromarone-treated
infarcted rats had signiﬁcantly higher myocardial free 15-F2t-
isoprostane.
As shown in Fig. 1C, compared with that in the sham group, XO
activity in the vehicle-treated infarcted group increased signiﬁ-
cantly. However, XO activity in the allopurinol and febuxostat
groups decreased signiﬁcantly compared with that in the vehicle-
and benzbromarone-treated infarcted groups.3.1.3. DHE staining in myocardium
DHE reacts with superoxide radicals to form ethidium bromide,
which in turn intercalates with DNA to provide nuclear ﬂuores-
cence as a marker of superoxide radical generation. As shown in
Fig. 2, postinfarction remodeling markedly enhanced the intensity
of the DHE staining in cardiomyocytes in the remote zone
compared with those in the sham. However, the intensity of the
ﬂuorescent signal in the allopurinol and febuxostat groups was
signiﬁcantly reduced relative to the vehicle and benzbromarone
groups.
Table 1
Cardiac morphology, hemodynamics, uric acid, and NE concentrations at the end of study.
Sham Infarction treated with
Parameters Vehicle Vehicle Benzbromarone Allopurinol Febuxostat
No. of rats 10 11 12 11 12
Body weight, g 325 ± 12 315 ± 15 305 ± 20 310 ± 15 312 ± 19
Heart rate, bpm 392 ± 15 413 ± 20 399 ± 18 412 ± 14 408 ± 18
LVESP, mm Hg 108 ± 5 99 ± 12 96 ± 14 103 ± 10 105 ± 12
LVEDP, mm Hg 7 ± 2 19 ± 3* 19 ± 3* 17 ± 4* 16 ± 5*
þdP/dt, mm Hg/s 7465 ± 376 3098 ± 425*y 2977 ± 379*y 3876 ± 319* 3988 ± 436*
-dP/dt, mm Hg/s 6538 ± 439 2765 ± 329*y 2832 ± 359*y 3654 ± 344* 3572 ± 309*
Infarct size, % 0 40 ± 3 41 ± 3 41 ± 2 42 ± 3
LVW/BW, mg/g 2.15 ± 0.25 3.16 ± 0.24* 2.97 ± 0.28* 3.05 ± 0.32* 2.97 ± 0.26*
RVW/BW, mg/g 0.52 ± 0.12 0.64 ± 0.15* 0.74 ± 0.18* 0.58 ± 0.15 0.57 ± 0.12
LungW/BW, mg/g 4.12 ± 0.30 5.12 ± 0.30*y 5.55 ± 0.46*y 4.59 ± 0.39 4.42 ± 0.38
Uric acid, mg/dl 0.75 ± 0.12 1.21 ± 0.23*‡ 0.82 ± 0.16 0.76 ± 0.12 0.71 ± 0.16
NE, mg/g protein 1.25 ± 0.17 2.75 ± 0.32*y 2.85 ± 0.25*y 1.73 ± 0.17* 1.64 ± 0.22*
Values are mean ± SD. BW, body weight; LungW, lung weight; LVEDP, left ventricular end-diastolic pressure; LVESP, left ventricular end-systolic pressure; LVW, left ven-
tricular weight; NE, norepinephrine; RVW, right ventricular weight. *P < 0.05 compared with sham; yP < 0.05 compared with infarcted groups treated with allopurinol and
febuxostat; ‡P < 0.05 compared with infarcted groups treated with benzbromarone, allopurinol and febuxostat.
T.-M. Lee et al. / Journal of Pharmacological Sciences 131 (2016) 28e36 313.1.4. Immunoﬂuorescent analyses
The tyrosine hydroxylase-immunostained nerve ﬁbers
appeared to be oriented in the longitudinal axis of adjacent myo-
ﬁbers (Fig. 3, upper panel). Tyrosine hydroxylase-positive nerve
density was signiﬁcantly increased in the vehicle-treated infarcted
rats than that in sham group. Allopurinol- and febuxostat-treated
rats show signiﬁcantly lower nerve density at the remote regions
than vehicle- and benzbromarone-treated rats (0.23± 0.12%,
0.18± 0.18% vs. 0.48± 0.21% in vehicle, 0.35± 0.19% in benz-
bromarone group). Similar to tyrosine hydroxylase results,Fig. 1. Myocardial superoxide (A), free 15-F2t-isoprostane (B) and XO activities (C) from the r
febuxostat-treated groups.densities of growth associated protein 43- (Fig. 3, lower panel) and
neuroﬁlament-positive (data not shown) nerves were signiﬁcantly
attenuated in the allopurinol- and febuxostat-treated infarcted rats
compared with those in vehicle- and benzbromarone-treated
infarcted groups. These morphometric results mirrored those of
norepinephrine contents.
3.1.5. NGF protein and mRNA expression
Western blot shows that NGF levels were signiﬁcantly upregu-
lated 3.9-fold at the remote zone in the vehicle-treated infarctedemote zone. *P < 0.05 compared with sham; yP < 0.05 compared with allopurinol-, and
Fig. 2. Detection of superoxide in myocardium by DHE staining. Compared with sham,
the DHE ﬂuorescence intensity in the myocardium of the vehicle-treated infarcted
group was signiﬁcantly increased. DHE staining (%) at the remote zone. Each column
and bar represents mean ± SD. A, sham (n ¼ 10); B, infarction treated with vehicle
(Veh, n ¼ 11); C, infarction treated with benzbromarone (Benz, n ¼ 12); D, infarction
treated with allopurinol (Allo, n ¼ 11); E, infarction treated with febuxostat (Feb,
n ¼ 12). Bar ¼ 50 mm *P < 0.05 compared with sham; yP < 0.05 compared with
allopurinol-, and febuxostat-treated groups.
Fig. 3. Immunoﬂuorescent staining for tyrosine hydroxylase and growth associated
protein 43 from the remote regions (magniﬁcation 400). Upper, tyrosine hydroxy-
lase. Tyrosine hydroxylase-positive nerve ﬁbers are located between myoﬁbrils and are
oriented longitudinal direction as that of the myoﬁbrils. Lower, growth associated
protein 43. A, sham (n ¼ 10); B, infarction treated with vehicle (Veh, n ¼ 11); C,
infarction treated with benzbromarone (Benz, n ¼ 12); D, infarction treated with
allopurinol (Allo, n ¼ 11); E, infarction treated with febuxostat (Feb, n ¼ 12).
Bar ¼ 50 mm. Each column and bar represents mean ± SD. *P < 0.05 compared with
sham; yP < 0.05 compared with allopurinol-, and febuxostat-treated groups.
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When compared with vehicle-treated infarcted rats, allopurinol-
and febuxostat-treated infarcted rats had signiﬁcantly lower NGF
levels at the remote zone. However, when compared with
allopurinol-treated infarcted rats, benzbromarone-treated
infarcted rats had signiﬁcantly higher myocardial NGF levels.
PCR ampliﬁcation of the cDNA revealed that the NGF mRNA
levels showed a 3.1-fold upregulation at the remote zone in the
vehicle-treated infarcted rats compared with sham-operated rats
(P < 0.001, Fig. 4 lower panel). In allopurinol-treated infarcted rats,
the NGF mRNA levels were signiﬁcantly decreased compared with
those in the benzbromarone-treated infarcted rats.
3.1.6. Electrophysiological stimulation
To further elucidate the physiological effect of attenuated sym-
pathetic hyperinnervation, ventricular pacing was performed. A
representative electrocardiogram record in a vehicle-treated
infarcted rat is shown in Fig. 5A. Arrhythmia score in sham-
operated rats was very low (0.1 ± 0.3) (Fig. 5B). In contrast, ven-
tricular tachyarrhythmias consisting of ventricular tachycardia and
ventricular ﬁbrillationwere induced by programmed stimulation in
vehicle-treated infarcted rats. Allopurinol and febuxostat treatment
signiﬁcantly decreased the inducibility of ventricular tachyar-
rhythmias compared with vehicle and benzbromarone treatment.
Carvedilol treatment also signiﬁcantly decreased the inducibility of
ventricular tachyarrhythmias compared with vehicle- and benz
bromarone-treated infarcted rats (both P < 0.05).
3.2. Part 2. Ex vivo study
To further conﬁrm the role of XO inhibitors acting as antioxi-
dants in modulating NGF levels, we determined the contribution of
nitrosative stress to NGF levels, using the peroxynitrite generatorSIN-1. As shown in Fig. 6, the peroxynitrite generator blocked the
attenuated effect of XO inhibitors on NGF levels.
4. Discussions
Our present study shows for the ﬁrst time that chronic
treatment for 4 weeks with urate-lowering agents with XO
Fig. 4. NGF protein and mRNA in homogenates of the LV from the remote zone. When
compared with vehicle (Veh)- and benzbromarone (Benz)-treated infarcted rats,
allopurinol (Allo)- and febuxostat (Feb)-treated infarcted rats had signiﬁcantly lower
NGF levels at the remote zone by quantitative analysis. Relative abundance was ob-
tained by normalizing the density of NGF protein against that of b-actin. Each mRNA
was corrected for an mRNA level of cyclophilin. Results are mean ± SD of 3 independent
experiments. *P < 0.05 compared with sham; yP < 0.05 compared with allopurinol-,
and febuxostat-treated groups.
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decreased arrhythmias after MI. Further, our results, which show
the inability of alternative urate-lowering agent without inhibi-
tion of the XO pathway to mimic the allopurinol effect on
norepinephrine, suggest that the effect of allopurinol on sympa-
thetic innervation is dependent of its antioxidative property.
Treatment with structurally-unrelated XO inhibitor, febuxostat,
signiﬁcantly reduced its NGF expression, providing further proof
that XO activities were the active component in postinfarction
sympathetic hyperinnervation. These results were consistent
with the beneﬁcial effects of allopurinol and febuxostat, as
documented structurally by reduction in cardiac nerve sprouting,
and DHE staining, molecularly by myocardial NGF protein and
mRNA levels, biochemically by myocardial norepinephrine, su-
peroxide, 15-F2t-isoprostane, peroxynitrite and XO activities, and
functionally by fatal ventricular tachyarrhythmias. Our results
were consistent with the notion that therapeutic XO inhibition
favorably affects a range of surrogate markers; however, treat-
ment using uricosuric agents without XO inhibition did not yield
similar beneﬁcial effects.
The effect of XO inhibitors on attenuated sympathetic innerva-
tion was supported by 3 lines of evidence.
1) MI was associated with increased urate levels and XO activities.
Our results were consistent with previous studies, showing that
a rise in serum urate level is common after MI and is caused by
either a fall in the glomerular ﬁltration rate or an increased urate
production (31). Recently, Kono et al (32) have shown that urate
as a proinﬂammatory molecule contributes signiﬁcantly to the
cell death-induced inﬂammatory responses in vivo. Inﬂamma-
tion has been shown to increase XO activities (33). Thus, it is not
surprising that XO activities were greater in infarcted rats
compared with those in sham rats.2) The beneﬁcial effects of XO inhibitors on attenuated sympa-
thetic innervation might be associated with decreased reactive
oxygen species levels. Allopurinol attenuated sympathetic
innervation by 52% compared with vehicle assessed by the
nerve intensity of tyrosine hydroxylase, whereas benzbromar-
one at an equivalent urate-reducing dose did not alter sympa-
thetic innervation at all. These results indicate that the neuronal
remodeling after infarction is subject to the regulation of reac-
tive oxygen species. The protective effects associated with
febuxostat in this model provide additional support for the role
of XO in the prevention of sympathetic hyperinnervation post-
MI. Allopurinol is a purine analogue that is subject to being
metabolized by many enzymes involved in purine and pyrimi-
dine synthesis metabolism, whereas febuxostat is not a purine
analogue. Febuxostat is only an inhibitor of XO and does not
inﬂuence the activity of other enzymes involved in purine or
pyrimidine synthesis or metabolism.
3) XO inhibitors attenuated the NGF levels through a superoxide
pathway. XO inhibitors are capable of attenuating sympathetic
innervation, as indicated with improved fatal arrhythmias. Su-
peroxide might be the mediator responsible for increased NGF
levels. SIN-1 signiﬁcantly increased the attenuated NGF levels in
infarcted rat hearts treated with XO inhibitors. Peroxynitrite has
been shown to activate activator protein-1 activation (34),
which in turn to activate the NGF promoter and enhance the
transcripts of NGF. The results reconﬁrmed our previous obser-
vations that attenuated NGF expression after MI is attributable
to XO-mediated reduced superoxide, and the contribution of
NADPH oxidase is relatively minimal (25). However, in that
study, we did no assess the differential effects of urate-lowering
agents on superoxide production. Thus, these results extended
our previous ﬁndings that only urate-lowering agents with XO
inhibition can attenuate sympathetic hyperinnervation after
infarction.
The role of sympathetic hyperinnervation in arrhythmic
vulnerability was conﬁrmed by the result that b-blockade by car-
vedilol attenuated pacing-induced ventricular arrhythmias. Sym-
pathetic hyperinnervation suppressed the expressions and
functions of myocardial transient outward current (Ito) and inward
rectiﬁer current (IK1) channels, and affected the repolarization of
myocardial cells and hence increased the vulnerability to ventric-
ular arrhythmia (35). It is not surprising to know that there was a
positive correlation between sympathetic nerve density and a
clinical history of ventricular arrhythmia (9). b-blockers have been
shown to inhibit NE's interactions with b-adrenergic G protein-
coupled receptors, thus preventing formation of second
messenger cAMP and reactive oxygen species, and attenuating
sympathetic hyperinnervation (36). Indeed, our results were
consistent with the ﬁndings of Wen et al (36), who showed that
excessively increased post-injury sympathetic nerve density was
responsible for the genesis of ventricular arrhythmia and that car-
vedilol inhibited sympathetic nerve sprouting and decreased the
inducibility of ventricular arrhythmias after MI.
4.1. Clinical implication
Our ﬁndings are of clinical interest given the high prevalence of
post-infarction arrhythmias. First, given the importance of XO in
the development of postinfarction sympathetic innervation, the
protective effect of allopurinol that we have shown here may have
clinical relevance. Ventricular ﬁbrillation is the most common
cause of sudden cardiac death and prematurely claims the lives of
~300,000 persons every year in the United States (37). So far, no
studies have directly addressed the question of whether or not the
Fig. 5. A. A representative sustained ventricular arrhythmia induced by ventricular pacing in an infarcted rat treated with vehicle. After eight basic stimuli at a cycle length of
120 ms, sustained ventricular tachyarrhythmias were observed (score: 7); B, inducibility quotient of ventricular arrhythmias by programmed electrical stimulation 4 weeks after MI
in an in vivo model. Each column and bar represents mean ± SD. *P < 0.05 compared with sham; yP < 0.05 compared with allopurinol-, febuxostat-, and carvedilol-treated groups.
Fig. 6. Effect of SIN-1 on XO inhibitors-induced myocardial nitrotyrosine and NGF levels in an isolated heart study. The allopurinol- and febuxostat-treated hearts had signiﬁcantly
decreased nitrotyrosine and NGF levels compared to vehicle. However, the nitrotyrosine and NGF levels cannot be attenuated after addition of SIN-1 compared with allopurinol
alone. n ¼ 5 each group. *P < 0.05 compared with vehicle-, allopurinol (Allo)/SIN-1-, and febuxostat (Feb)/SIN-1-treated groups.
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bility to ventricular arrhythmias after MI. Second, our results
showed that the therapeutic targeting of free radicals represents an
attractive strategy to reduce arrhythmias. Many known triggers of
oxidative stress are linked to an increased risk of fatal arrhythmias.
Decreasing oxidative stress may therefore be a promising novel
strategy to reduce arrhythmic risk.
4.2. Study limitations
There are some limitations in the present study that have to be
acknowledged. There are well-established interspecies differences
in intrinsic levels of myocardial XO activity (38). Rats used in this
study have relatively high levels of myocardial XO activity during
myocardial ischemia, whereas the activity in humans is compara-
tively low (39). Thus, our ﬁnding cannot necessarily be extrapolated
to species with comparatively low activities of XO. It is not sur-
prising that clinical trial (OPT-CHF) designed to demonstrate the
efﬁcacy of long-term oxypurinol, a major metabolite of allopurinol,
treatment in heart failure patients showed no therapeutic beneﬁt
(40). However, subgroup analysis of the OPT-CHF study showed
that heart failure patients with elevated baseline uric acid9.5 mg/
dl have a favorable response to therapy with oxypurinol (40).
Higher uric acid levels may represent a valuable biomarker of XO
activity. The observation further conﬁrmed our notion that XO in-
hibitors are more effective in animals or humans with higher XO
activity.
5. Conclusions
These data show that superoxide status determines sympathetic
hyperinnervation after infarction and that antioxidant activities by
administering XO inhibitors attenuate sympathetic hyperinnerva-
tion. Treatment strategies that reduce XO activation may therefore
represent a novel option to prevent arrhythmias after MI.
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